Market Overview

Hearing Amylin Considering Sale -Reuters


Amylin (NASDAQ: AMLN) is considering a sale of the company, according to sources cited by Reuters. Amylin is attempting to fight off a law suit by investor Carl Icahn. The company recently rejected a $3.5 billion takeover offer from Bristol-Myers Squibb (NYSE: BMY).

Posted-In: News Rumors Insider Trades M&A Pre-Market Outlook


Related Articles (AMLN + BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters